Six years ago, at age 49, Julie Gregory paid an online service to sequence her genes, hoping to turn up clues about her poor circulation, blood-sugar swings and general ill health. Instead she learned she had a time bomb hidden in her DNA: two copies of a gene variant, ApoE4, that is strongly linked to Alzheimer’s. Most Americans with this genotype go on to develop late-onset dementia.
The Inova Health System will formally open its doors to new ideas by launching its personalized health accelerator on Nov. 30.
The event begins at 6:15 p.m. and will be held at the Inova Center for Personalized Health at 3225 Gallows Rd. in Fairfax. It includes a ribbon cutting, networking, keynote speeches and a tour of the facility.
A team of five Johns Hopkins University students won first place and $5,000 at the fifth annual Pfizer Case Competition at the Johns Hopkins Carey Business School earlier this month.
Fifteen Johns Hopkins scientists are among 3,000 individuals included on the annual Highly Cited Researchers list compiled by Clarivate Analytics, which was previously part of Thomson Reuters.
That Indians are not only heading global IT giants like Google and Microsoft but also a number of startups in diverse sectors, including biotechnology, across the US is evident from the fact that of the 52 companies operating out of the two innovation hubs in Rockville and Germantown in Maryland 11 are either headed or run by Indians.
From mobile technology platform connecting doctors and patients to pre-market cybersecurity for IoT (Internet of Things) devices, Indian Americans are the driving force behind several firms at the two innovation hubs managed by BioHealth Innovation, Inc, a non-profit public-private partnership, which aids early stage biotechnology companies from research to commercialization.
High-income countries are grappling with the challenge of caring for aging populations, many of whose members have chronic illnesses and declining capacity to manage activities of daily living. The 2017 Commonwealth Fund International Health Policy Survey of Older Adults in eleven countries showed that US seniors were sicker than their counterparts in other countries and, despite universal coverage under Medicare, faced more financial barriers to health care.
When: Tuesday, December 5, 2017 6:30 p.m. – 8:30 p.m. EST
Where: All Set Restaurant & Bar 8630 Fenton St. Silver Spring, MD 20910
It’s that time of the year again! Please join Capital Region chapter of Women In Bio as we celebrate the conclusion of an amazing 2017 at All Set Restaurant & Bar in Silver Spring, MD. Come mix & mingle with friends old and new over drinks and hors d’oeuvres, learn about the opportunities and resources that you have access to as WIB members, and participate in our raffle to win exciting prices!
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Maryland Tech Council announced today that Nora D. Volkow, M.D., Director of the National Institute on Drug Abuse, National Institutes of Health (NIH) will kick off its new Innovation Speaker Series. Dr. Volkow will discuss the current state of the opioid crisis nationally and locally. Additionally, her presentation will cover what research has shown about this particular addiction, its prevention and treatment, and how science may help end the massive public health crisis. Key industry leaders are expected to attend this inaugural series event, which will take place Wednesday, November 29, 2017 at the Universities at Shady Grove from 7:30-9:30 a.m.
The Johns Hopkins University and Deerfield Management announced today the creation of Bluefield Innovations, a collaboration designed to catalyze the development of early stage therapeutics. Funded by Deerfield, an investment management firm committed to advancing health care, Bluefield Innovations will provide up to $65 million in initial funding over five years to support the commercialization of early stage therapeutic research at Johns Hopkins, with additional funding available to advance research that shows strong commercial potential.
